Table 1.
Baseline Characteristics of the Included Studies.
| Study | MINORS score a | FU (m) | Patients (n) | Mean age (y) | Male | DM | DL | HT | Smoking | CAD | Rutherford stage 2–3/4/5–6 (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Canaud et al 16 | 12 (16) | 24 | 69 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Bosiers et al 17 | 10 (16) | 12 | 31 | 76 | 17 (55) | 14 (45) | 5 (16) | 18 (58) | 5 (16) | N/A | 0/61/39 |
| Iezzi et al 21 | 8 (16) | 12 | 23 | 69.6 | 16 (70) | 21 (91) | 13 (57) | 11 (48) | 14 (61) | N/A | 0/60/40 |
| Gallagher et al 22 | 16 (24) | 24 | 74 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/100 b |
| Control (PTA) | 72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/100 b | ||
| Rastan et al 18 | 8 (16) | 12 | 70 | 74.3 | 39 (56) | 55 (79) | 55 (79) | 64 (91) | 7 (10) | 24 (34) | 0/34/66 |
| Shammas et al 26 | 18 (24) | 12 | 25 | 70.7 | 17 (68) | 18 (72) | 20 (83) | 21 (84) | 15 (60) | 11 (44) | 0/48/52 |
| Control (PTA) | 25 | 71.8 | 15 (60) | 14 (56) | 18 (72) | 21 (84) | 15 (60) | 14 (56) | 0/48/52 | ||
| Bosiers et al 19 | 16 (24) | 12 | 64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/100 b |
| Control (PTA) | 79 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/100 b | ||
| Sultan et al 20 | 18 (24) | 36 | 38 | 68 | 22 (58) | N/A c (77) | N/A c (77) | N/A c (62) | 33 (87) | 14 (37) | 0/18/81 |
| Control (PTA) | 42 | 70 | 25 (60) | N/A c (82) | N/A c (78) | 29 (69) | 38 (90) | N/A c (34) | 0/21/79 | ||
| Kokkinidis et al 23 | 14 (24) | 24 | 76 | 69.5 | 57 (75) | 49 (64) | N/A | 66 (87) | 42 (55) | 25 (33) | 0/100 b |
| Control (PTA) | 237 | 70.1 | 160 (68) | 186 (78) | N/A | 204 (86) | 127 (54) | 122 (52) | 0/100 b | ||
| Todd et al 24 | 14 (24) | 36 | 79 | 70 | 55 (70) | 60 (76) | 53 (67) | 77 (97) | 49 (62) | N/A c (60) | 0/30/70 |
| Control (PTA) | 339 | 71 | N/A c (60) | N/A c (71) | N/A c (64) | N/A c (91) | N/A c (65) | N/A c (53) | 0/33/67 | ||
| Zia et al 25 | 16 (24) | 18 | 159 | 67 | 91 (57) | 97 (61) | 104 (65) | 143 (90) | 74 (47) | 65 (41) | 0/21/79 |
| Control (PTA) | 183 | 67.3 | 116 (63) | 117 (64) | 126 (69) | 168 (92) | 85 (46) | 99 (54) | 0/16/84 | ||
| Rastan et al 27 | 20 (24) | 12 | 40 | 71.5 | 28 (70) | 28 (70) | 37 (93) | 37 (93) | 6 (15) | 19 (48) | 35/10/55 |
| Control (DCB) | 40 | 72.7 | 33 (83) | 24 (60) | 31 (77) | 40 (100) | 4 (11) | 16 (40) | 23/23/55 | ||
| Zeller et al 28 | 20 (24) | 12 | 32 | 73.4 | 26 (81) | 24 (75) | 29 (91) | 31 (97) | 23 (72) | 19 (59) | 31/6/63 |
| Control (DCB) | 34 | 76.5 | 25 (74) | 20 (59) | 24 (71) | 31 (91) | 17 (50) | 15 (44) | 24/12/65 |
Data are given as n (%) unless stated otherwise.
Abbreviations: CAD, coronary artery disease; DCB, drug-coated balloon; DL, dyslipidemia; DM, diabetes mellitus; FU, follow-up; HT, hypertension; PTA, percutaneous transluminal angioplasty.
a
The MINORS is used to assess the quality of the included studies. Values are given as score (maximum possible score).
b
Data are given as Rutherford stage 2–3/4–6, that is, intermittent claudication/chronic limb-threatening ischemia (%).
c
In the demographics table only the exact percentage is given. However, this percentage cannot be converted into exact number of patients.